Background-An algorithm to classify heart failure (HF) end points inclusive of contemporary measures of biomarkers and echocardiography was recently proposed by an international expert panel. 
C
linical research and epidemiological studies of heart failure (HF) have been hindered by the lack of a consensus definition of HF as a recurrent event or end point that is valid, repeatable, and cost-effective. [1] [2] [3] [4] The pleomorphic nature of the HF syndrome contributes to the difficulty in defining and classifying HF. HF manifestations can be vague, as well as shared with other conditions that are often comorbid with HF, such as respiratory and renal disease. 5 Thus, the current gold standard for HF classification is expert review of medical records and adjudication, 6, 7 although classification of HF by an expert reviewer panel is subject to more misclassification than for events, such as myocardial infarction and stroke. A standardized and repeatable event review by a reviewer panel is expensive and time consuming and thus not practical for most studies, and further difficulties include the use of diverse classification schema. Although the Framingham, modified Boston, and National Health and Nutrition Examination Survey classification schemas are widely used, their relevance to contemporary classifications of HF events is questionable 4 because most extant HF classification schema were created before the clinical use of biomarkers and cardiac imaging in HF diagnosis and care. Furthermore, they largely do not consider whether an HF event is new or decompensated.
regulators, and pharmaceutical industry scientists published recommendations for an updated classification of HF for clinical trials and observational studies of HF. 4 Extending prior HF classifications, biomarker and echocardiographic information was included, and the distinction between 3 types of HF events was emphasized (Table 1 ). The 3 types of HF events include those with a new diagnosis, a new event without prior HF, or a new event with history of HF. The first 2 groups largely differ by severity and setting of presentation. Henceforth, we refer to this expert panel as the CCT Workshop 4 and to their proposed HF event definition as the HF algorithm. As far as we know, this algorithm has yet to be implemented or evaluated; therefore, we operationalized and automated a modified version of the HF algorithm proposed by the CCT for hospitalized events of HF regardless of history of HF. We examined its performance characteristics on data abstracted by trained personnel from medical records of a population-based sample of HF hospitalizations in 4 US communities. Hospitalizations included all men and women aged ≥55 years with International Classification of Diseases (ICD)-coded discharge diagnoses related to HF during 2005-2007 in these areas. 8 We tested the concordance of this automated HF classification algorithm with an established panel of standardized physician reviewers of the Atherosclerosis Risk in Communities (ARIC) study. 8 
Methods

Automated Classification of HF
To examine the applicability and usefulness of the HF algorithm in population settings, we ascertained the HF classification criteria items from hospital medical records and thus applicable to clinical research studies using electronic health records or epidemiological surveillance studies. Accordingly, we deferred classification of HF according to history of HF and instead examined performance of a modified version of the HF algorithm that does not consider HF history. We modified the criteria identified by the CCT as HF as a new event, to achieve wider interest and applicability (Table 1) . If a classification algorithm performs sufficiently well, the distinction of events according to their prevalent or incident nature is typically done as an analytic step and not as an event classification category. Furthermore, we did not include death caused by HF. See Methods section in the online-only Data Supplement for details. Given that the purpose of this study is to test the automated algorithm in the real-world setting of hospital medical records, there was neither an echocardiogram reading center nor a central laboratory for the measurement of brain natriuretic peptide (BNP). Hospital records that made no reference to measures of either ejection fraction or BNP/N-terminal-pro-BNP were considered not indicative of HF for the missing measure. Records missing both BNP and ejection fraction measures were excluded to preserve the validity of the comparison.
Study Population
The ARIC study has conducted population-based retrospective surveillance for coronary heart disease since 1987. 8 HF has been a target for community surveillance in ARIC since 2005, based on a sample of hospital discharges in 4 geographically defined areas in the United States, for all residents aged ≥55 years. 9 Because ARIC began automatically classifying some of the eligible hospitalizations in 2008, we limit this analysis to [2005] [2006] [2007] . The 4 ARIC study areas are the city of Jackson, MS; Washington County, MD; 8 northwestern suburbs of Minneapolis, MN; and Forsyth County, NC. In 2005, these 4 regions had an overall population of 177 000, aged ≥55 years. Nonblack and nonwhite race groups are excluded because of small numbers. The institutional review boards from each study site (Wake Forest University, University of Minnesota, Johns Hopkins University, and the University of Mississippi) approved the ARIC study.
Ascertainment of Hospitalizations for HF
Annually, lists of hospital discharges containing a code from a target list of ICD-Ninth Revision-Clinical Modification (ICD-9-CM) codes were obtained from the hospitals in the 4 ARIC communities (31 hospitals in 2005). See Table I in the online-only Data Supplement for a list of targeted HF ICD-9-CM codes. For 91% of the sample, a 428 for congestive HF was listed as one of the codes. For all community residents, aged ≥55 years, hospitalizations were sampled using stratified probabilistic sampling by HF ICD-9-CM code, age, sex, race, and area of residence in the community. Sampling probabilities by strata were selected to optimize variance estimates for HF event rates within strata, and based on the prespecified maximum number of events planned for data abstraction. 9 Results are weighted for these sampling probabilities to maintain population estimates for the distribution of ICD codes and other factors that may affect concordance.
Abstraction and Classification of HF Events
Medical records were abstracted by trained study personnel following a standardized protocol. Each record was first abstracted to answer 6 screening questions for acute decompensated HF (ADHF); if any of the answers were positive a full abstraction ensued. The 6 screening items included mention of any of the following: increasing or new onset shortness of breath, peripheral edema, paroxysmal dyspnea, orthopnea, hypoxia, or HF as a cause for hospitalization. Of all records with a HF ICD code, 36% did not meet the screening criteria and were not abstracted in full and were not included in these analyses. A separate analysis examined the effect of this efficiency-based screening in a subset of 797 medical records, based on a full data abstraction for medical records that would have been screened out. We found that 48% (n=386) had either BNP or a measure of ejection fraction and thus would have qualified for the analysis. Of the 386 medical records with biomarker or imaging information, 11.7% were found to have definite or possible ADHF per ARIC reviewer panel. In comparison, 68% of the records fully abstracted for this study had definite or possible HF by ARIC reviewer panel. Thus, screening before full record abstraction was effective in yielding a low number of false negatives.
Full record abstraction using the HF abstraction form comprehensively incorporated the pertinent elements for classification of HF, and history of comorbid conditions as described previously (abstraction form available at http://drupal.cscc.unc.edu/aric/hfforms). 9 A computer-based classification was applied to the abstracted data to arrive at the appropriate classification for the CCT automated †Modified to include all 4 categories of HF as a new event (column 2) to include those with or without a prior history of HF documented in the medical. Outpatient visits are not included in the study sample.
algorithm (Tables 1 and 2 ). Secondarily, conventional HF criteria (Framingham, 10 Boston, 11 National Health and Nutrition Examination Survey, 12 and Gothenburg) 13 were also defined from abstracted data (results are presented in the online-only Data Supplement). 9 Eligible hospitalizations were independently reviewed by 1 or 2 trained physician reviewer(s) with resolution of disagreements by an adjudicator. Physicians followed ARIC HF classification guidelines when evaluating medical records, and applied judgment to arrive at a classification of definite ADHF, possible ADHF, chronic HF, HF unlikely, or unclassifiable. 9 Here, definite and possible ADHF have been combined into a single category of ADHF present, and the other 3 categories have been combined as ADHF absent.
Classification of HF Events in ARIC
The ARIC classification guidelines have been described. 9 Classification of definite ADHF required clear evidence of HF with active decompensation and the presence of HF with certainty as to the cause of the presentation. Possible ADHF included criteria similar to definite ADHF, without as much certainty that HF is the cause of the presentation. A classification of chronic HF applied to a history of HF that was not decompensated.
Statistical Analysis
All estimates were weighted to account for the sampling design and to maintain the population distribution of ICD codes and other factors that may affect concordance. We cannot reliably link hospitalizations to identify repeat events; therefore, all hospitalizations are assumed to be independent. The positive and negative agreement, the κ coefficient, and the prevalence-and bias-adjusted κ were calculated relating the automated algorithm to the ARIC reviewer panel classifications. The prevalence-and bias-adjusted κ were calculated because the prevalences of positive and negative tests were not balanced, which can result in a κ with low reliability even when observed agreement is good. 14, 15 Measures of validity were calculated for the components of the automated algorithm individually and for the schema overall. Positive and negative predictive values were calculated for several different disease prevalences. 16 Formulas are specified in table footnotes.
Results
There were 2729 sampled hospitalizations eligible for review during 2005-2007, which resulted in 15 484 events after applying weights to account for sampling fractions. The tables and their discussion refer to the weighted number of events. Of these, 10.5% (n=1630 weighted) were missing BNP measures Initiation or increase in treatment with loop diuretics or intravenous vasoactive agents. The automated algorithm's criteria specify that this treatment should be specifically for the above symptoms; however, our abstraction only confirms that such treatment was provided during this hospitalization
Biomarkers and imaging, ≥1 of the following 1. Elevated BNP (≥400 ng/L*) or elevated NT-pro-BNP using age-defined cut points † Or 2. LVEF <40% Or 3. Moderately elevated BNP (100-400 ng/L) or NT-pro-BNP † (defined as less than age cut points) and documentation of LVEF <40% or diastolic dysfunction All 3 criteria elements must be met to define a heart failure event. BNP indicates brain natriuretic peptide; HF, heart failure; JVD, jugular venous distention; LVEF, left ventricular ejection fraction; and NT, N-terminal.
*SI units shown of ng/L=pg/mL. †Elevated NT-pro-BNP defined as: if <50 y then ≥450 ng/L; if 50-75 y then ≥900 ng/L; and if 75 y then ≥1800 ng/L. Moderately elevated NT pro-BNP defined with 300 ng/L as the bottom cut point for all age groups: if <50 y then 300-450 ng/L; if 50-75 y then 300-900 ng/L; and if 75 y then 300-1800 ng/L. In each group the mean age was 75 years, with 51% to 52% women, and 28% to 30% blacks. Hypertension (83%) and diabetes mellitus (46% to 48%) were common for both groups. Table 4 shows the characteristics of those classified with agreement and disagreement when comparing the automated algorithm with the ARIC reviewer panel. The overt differences between groups were few, but informative. The frequency of end stage renal disease was highest (34%) in those without ADHF by both criteria, and then next highest (21%) for those with ADHF per the automated algorithm, and not by ARIC reviewer panel. The mean levels of BNP and N-terminal-pro-BNP were visibly lower in the group classified as ADHF absent by the automated algorithm but present according to the ARIC reviewer panel. Those given diuretics were more likely to be classified with agreement as ADHF present (85% of those correctly classified, as compared with 55% to 69% for those misclassified). Table 5 shows measures of test validity calculated for the automated algorithm and its components, compared with the ARIC reviewer panel as a referent. The sensitivity was 0.68 and specificity 0.75 for the automated algorithm overall, with a positive predictive value of 0.85 and negative predictive value of 0.53. The prevalence of ADHF was 68% in this enriched sample of hospitalized events. Because predictive values differ according to prevalences, we calculated predictive values for lower disease prevalences (eg, for a prevalence of HF in the sample of 25%, the positive predictive value=0.48 and negative predictive ADHF indicates acute decompensated heart failure; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; HF, heart failure; and NT, N-terminal. *All numbers were weighted to account for sampling fraction. †Hospitalizations were screened and include only those that mention ≥1 of 6 signs or symptoms of ADHF.
value=0.88). As for the individual components of the algorithm, notably, elevated BNP or N-terminal-pro-BNP taken in isolation showed comparable levels of validity to the algorithm overall (a sensitivity of 0.78 and specificity of 0.64), although this represents a smaller group (81% of the sampled hospital records) with nonmissing biomarkers. In Table 6 (also in Table IV in the online-only Data Supplement), the agreement and validity statistics for ADHF by the ARIC reviewer panel were compared with the automated algorithm. The prevalence-and bias-adjusted of κ does not suggest a large influence of internal imbalance in these data on the κ statistic.
Discussion
We assessed the applicability and classification properties of an algorithm proposed for the classification of HF end points in clinical trials or observational studies, which incorporates diagnostic tools routinely used in current medical practice. We evaluated the performance of this algorithm in the setting of hospitalizations sampled from a large number of hospitals from 4 regions of the United States that participate in a National Heart, Lung, and Blood Institute-sponsored epidemiology study of HF. The evaluation of an automated HF algorithm that incorporates biomarkers and echocardiographic measures is novel in the context of a large, populationbased sample of hospitalizations and is notable for its scope and generalizability. In addition to signs and symptoms as elements of the HF syndrome, the availability of echocardiographic imaging and biomarker information abstracted from records generated in the course of routine medical care indicate that an application of an automated algorithm is feasible under these circumstances and was successful. We found that 89.5% of hospital medical records sampled during the period 2005-2007 contained either BNP/N-terminal-pro-BNP or echocardiographic measures suitable for use in applying this algorithm. Furthermore, by adding detail and some modifications to the definitions published by Zannad et al, 4 we were able to operationalize an algorithmic definition for HF. The ability to apply an automated algorithm to real-world settings and electronic health record highlights the potential efficiencies in the classification of HF events for research and administrative applications based on hospital medical records.
To our knowledge this is the first study to assess the classification performance of this algorithm and its validity relative to a standardized HF classification method by a panel of physician reviewers. Because HF is a clinical syndrome for which there is no consensus definition, its classification is difficult. Additional complexity is added by the episodes of acute decompensation that characterize HF. This study focused on an accurate and reproducible algorithmic classification of ADHF. On the basis of 15 484 (weighted) hospitalizations sampled during 2005-2007 from all hospitals that serve the residents of 4 regions in the United States, we found modest agreement between ADHF defined by the automated algorithm and by the ARIC reviewer panel (κ of 0.39, prevalence-and bias-adjusted κ of 0.41). Chance-adjusted agreement, as measured by Cohen's κ, was slightly higher here than agreement between existing HF criteria and the ARIC reviewer panel as shown in a prior publication (Framingham K=0.32, Modified Boston K=0.18). 9 Given that the ARIC HF panel reviewers considered BNP measures and echocardiography findings in classifying HF events, we expected the automated algorithm (which includes criteria elements for these measures) to have better agreement with ARIC's ADHF than the other schema considered which do not consider these measures. In addition, existing HF schemas do not distinguish ADHF from chronic HF, whereas the automated algorithm and the ARIC reviewer classification do. Using ARIC's classification of ADHF as a referent standard, we found a sensitivity of 0.68 (95% confidence interval, 0.67-0.69) for the automated algorithm (ie, 68% of those with ADHF by the ARIC reviewer panel [reference standard] were also found to have ADHF per automated algorithm). Thus, 32% of those with ADHF were missed as false negatives applying the automated algorithm. Specificity was estimated as 0.75 (95% confidence interval, 0.74-0.76), implying that 75% of those who did not have ADHF by the reference standard also were found not to have ADHF by the automated algorithm (true negatives), and 25% of those without HF were false positives according to the automated algorithm. Using the ARIC reviewer panel as the referent standard, the automated algorithm performed with higher specificity, and lower sensitivity compared with other commonly used HF classification schema (Table V in the online-only Data Supplement). The automated algorithm did not perform at higher validity on both sensitivity and specificity when compared with the existing criteria, thus the relative value of sensitivity and specificity, and the cost of each type of misclassification need to be considered in the particular setting for which the classification of HF events is needed. The varied settings in which HF classification may be applied include the identification of potential participants with HF for a clinical trial, the identification of HF as an adverse events, and casefinding efforts that search through large databanks of electronic medical records.
Overall the automated algorithm had a better balance of sensitivity and specificity than any 1 individual component. The overall balance between sensitivity and specificity for the automated algorithm was closest to that for the BNP levels as an individual criterion element, although the biomarkers achieved higher sensitivity than specificity. Of note, hospital records containing BNP measures may reflect a different spectrum of disease or patient population than the overall sample of hospitalized residents of these study areas. Because biomarkers and echocardiographic measurements may be performed differentially in clinical settings, the automated algorithm is not likely to perform as well in circumstances where these measures would not be obtained routinely. Furthermore, our focus is the performance of this algorithm in real-world settings, and thus we did not limit the analysis to those with both measures. We would expect different results in a population that had both biomarkers and echocardiogram measures performed during a hospitalization, but both of these measures are not routinely obtained in HF hospitalizations.
Our study material included only hospitalizations lasting ≥24 hours. This may be a limitation in that milder cases of ADHF that could have been managed in the emergency department or admitted overnight to observation care would mostly be missed here. It is, therefore, unknown how the automated HF classification algorithm performs on data that include milder forms of ADHF. An additional limitation is that eligible hospital records with a qualifying ICD code for HF were abstracted only in part when the record did not include reference to increasing, or new onset shortness of breath, peripheral edema, paroxysmal dyspnea, orthopnea, hypoxia, or documentation that the reason for the event was HF. Across all hospitals included in this study, 36% of medical records did not meet the above screening criteria and were not abstracted in full. A calibration substudy of hospital records that did not meet these inclusion criteria and were fully abstracted (n=797) found that only 48% of those records that were screened out would have met criteria for classification using this automated algorithm, and that only 11.7% of those were identified as ADHF by ARIC. Thus, the impact of the criterion to select hospital records eligible for full abstraction on the results reported here is, therefore, quite small. Finally, as expected in the setting of communitybased hospitals, the biomarker assays and echocardiography measurements were not interpreted in a central reading center ADHF indicates acute decompensated heart failure; ARIC, atherosclerosis risk in communities; FN, false negative; FP, false positive; NPV, negative predictive value; PABAK, prevalence-and bias-adjusted κ; and PPV, positive predictive value; TN, true negative; and TP, true positive. *All numbers were weighted to account for sampling fractions.
or laboratory; therefore, some (unmeasured) variability is to be expected. Further studies should assess this algorithm in other settings, such as in a clinical trial, in which the goal is usually to define HF end points of ADHF in those known to have HF. Although centrally analyzed biomarker levels and centrally read imaging may be available from most clinical trials at baseline, it is relevant to note that many large multicenter clinical trials with HF hospitalization as an end point are also dependent on the clinical infrastructure for imaging and biomarker measures, in place of a centralized processing of these measures. 4 Among the strengths of this report are the novelty of the application of an automated algorithm for the classification of HF in a population-based setting and the rigorous evaluation of its performance characteristics in contemporaneous hospital-based practice. Additional strengths include the use of a large database of hospital records sampled to represent hospitalizations among the residents of 4 regions and their abstraction by trained study personnel following a standardized protocol. Because as of yet, there is no agreed-on gold standard to classify HF, a systematic physician review and classification according to standardized criteria represents the best available gold standard. Our reliance on a comprehensive and standardized protocol for the classification of ADHF that included a panel of calibrated physician reviewers adds strengths to the information reported here.
In conclusion, we were able to apply an algorithm recommended by an international panel of experts for the classification of HF to medical records sampled from diverse hospitals in geographically well-defined areas in the United States, and to automate this algorithm efficiently for use on data abstracted from records by trained personnel. The validity (accuracy) of the automated algorithm for ADHF was moderate at best compared with the classification of ADHF by ARIC's reviewer panel, although the agreement and specificity for the automated algorithm were greater than for the commonly used HF criteria that do not account for contemporary measures of BNP or echocardiography (Table V in the online-only Data Supplement). The development of HF classification criteria that agree with the highest reference standard of physician reviewer classification and their evaluation in the setting of medical practice are priorities for clinical and population-based research. If such an algorithm is used to classify all hospital admissions rather than those with high prior odds of HF as done in this study, then the concordance will be extremely high, as most records will not have HF by either criterion.
Diastolic dysfunction, a common finding in the elderly population without HF, does not contribute much to the ability to classify HF. Unlike with systolic dysfunction, the CCT algorithm requires that those with diastolic dysfunction must also have moderately elevated biomarkers to meet criteria for ADHF. It is possible that uniform measurements of diastolic parameters, which are not often reported in clinical echocardiograms, and research to define the appropriate set of parameters to best define diastolic dysfunction may improve its use for classification. The ability to classify ADHF with an up-to-date, automated classification algorithm and evaluate its performance characteristics is a critical step toward the establishment and standardized application of consensus criteria for HF. Advantages derived from their use would apply to the use of large medical records database resources, as well as efficiencies in time and costs.
